231 related articles for article (PubMed ID: 18841188)
1. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
Kunac DL; Harrison-Woolrych M; Tatley MV
N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
[TBL] [Abstract][Full Text] [Related]
2. Reporting adverse reactions to medicines.
Ferguson R
Nurs N Z; 1999 Dec-2000 Jan; 5(11):11. PubMed ID: 12008207
[No Abstract] [Full Text] [Related]
3. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
[TBL] [Abstract][Full Text] [Related]
4. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
Robson H; Braund R; Glass M; Ashton J; Tatley M
Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
[TBL] [Abstract][Full Text] [Related]
5. Hypnosedative access and risk of harm.
Menkes DB; Shieffelbien LM; Huthwaite M
N Z Med J; 2011 Nov; 124(1345):69-73. PubMed ID: 22072169
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants].
Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML
Therapie; 1997; 52(2):97-103. PubMed ID: 9231502
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance of serious adverse drug reactions in New Zealand children.
Kunac D; Tatley MV; Grimwood K; Reith DM
Arch Dis Child; 2012 Aug; 97(8):761-2. PubMed ID: 22563042
[No Abstract] [Full Text] [Related]
8. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
9. [Regional Centers of Pharmacovigilance: a complementary source of efficiency].
Mazé F; Bégaud B
Therapie; 1998; 53(4):397-400. PubMed ID: 9806011
[TBL] [Abstract][Full Text] [Related]
10. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
11. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
Ghosh D; Skinner M; Ferguson LR
Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
[TBL] [Abstract][Full Text] [Related]
12. National Centre for Adverse Reactions Monitoring report for the period 1 July, 1994 to 3 June, 1996.
Pillans P
N Z Med J; 1997 Oct; 110(1053):383-5. PubMed ID: 9364188
[No Abstract] [Full Text] [Related]
13. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
Miller M; Turner N
N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
[No Abstract] [Full Text] [Related]
14. The role of data mining in pharmacovigilance.
Hauben M; Madigan D; Gerrits CM; Walsh L; Van Puijenbroek EP
Expert Opin Drug Saf; 2005 Sep; 4(5):929-48. PubMed ID: 16111454
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacovigilance as new direction of research].
Gaszner G; Makkos Z; Gaszner P
Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
[TBL] [Abstract][Full Text] [Related]
16. The New Zealand Centre for Adverse Reactions Monitoring: a source of practice-based evidence.
Savage R
J Prim Health Care; 2013 Jun; 5(2):170-3. PubMed ID: 23748404
[No Abstract] [Full Text] [Related]
17. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Clark DW; Harrison-Woolrych M
Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
[TBL] [Abstract][Full Text] [Related]
18. New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).
Shin JY; Jung SY; Ahn SH; Lee SH; Kim SJ; Seong JM; Chung SY; Park BJ
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1115-22. PubMed ID: 25251052
[TBL] [Abstract][Full Text] [Related]
19. [The Swiss Centre of Pharmacovigilance].
Kuhn M; Hartmann K; Gartmann J
Therapie; 1993; 48(5):465-7. PubMed ID: 8146826
[TBL] [Abstract][Full Text] [Related]
20. The monitoring of adverse events following immunization.
Tatley M
N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
